FDA Approved: RABEPRAZOLE SODIUM — Supplemental Application (Lannett Company, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Lannett's generic rabeprazole sodium (ANDA 090678), authorizing its marketing as a proton pump inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duodenal Ulcer
• Erosive Esophagitis
• Gastric Ulcer
• Gastroesophageal Reflux Disease
• Maintenance of Healing of Erosive Esophagitis

Drugs mentioned

• Rabeprazole sodium (rabeprazole)

Snippet

SUPPL AP for RABEPRAZOLE SODIUM (RABEPRAZOLE SODIUM)